Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis
Public ClinicalTrials.gov record NCT00090129. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicentre, Randomised, Double-blind, Placebo Controlled Phase III Study of Subcutaneously Administered Onercept in the Treatment and Re-treatment of Subjects With Moderate to Severe Plaque Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The is a double-blind, placebo-controlled, randomized, and multicenter study consisting of a first treatment (FT) period followed by either an observation (OB) period and a re-treatment (RT) period or an open-label (OL) treatment period, depending on FT period response, and a 4-week safety follow-up (FU) period. The purpose of this study is to evaluate the safety and efficacy of onercept, to be administered as 150 milligram (mg) three times a week, compared to matching placebo, for the induction of remission in subjects with moderate to severe plaque psoriasis.
Study identification
- NCT ID
- NCT00090129
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 854 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2004 (Type not available)
- Primary completion
- Jun 2005 (Actual)
- Completion
- Jun 2005 (Actual)
- Last update posted
- Oct 22, 2013
2004 – 2005
United States locations
- U.S. sites
- 37
- U.S. states
- 17
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Bressnick Gibson Parker Dinehart Sangster Dermatology, P.A. | Little Rock | Arkansas | 72205 | — |
| Associates in Research Inc. | Fresno | California | 93710 | — |
| University of California, Irvine | Irvine | California | 92697 | — |
| Therapeutics Clinical Research | La Jolla | California | 92037 | — |
| University of California | San Francisco | California | 94108 | — |
| Clinical Research Specialists Inc. | Santa Monica | California | 90404 | — |
| Solano Clinical Research | Vallejo | California | 94589 | — |
| Dermatology Specialists Inc | Vista | California | 92083 | — |
| Colorado Medical Research Center | Denver | Colorado | 80210 | — |
| Cherry Creek Research, Inc. | Denver | Colorado | 80246 | — |
| Longmont Clinic PC | Longmont | Colorado | 80501 | — |
| The Savin Center P.C. | New Haven | Connecticut | 06511 | — |
| Dermatology Associates, P.C. at the Washington Hospital CTR | Washington D.C. | District of Columbia | 20010 | — |
| North Florida Dermatology Associates, P.A. | Jacksonville | Florida | 32204 | — |
| Jacksonville Center for Clinical Research | Jacksonville | Florida | 32216 | — |
| International Dermatology Research | Miami | Florida | 33144 | — |
| Atlanta Dermatology Vein & Research Center | Alpharetta | Georgia | 30005 | — |
| Scott D. Glazer, MD | Buffalo Grove | Illinois | 60089 | — |
| University of Michigan Department of Dermatology | Ann Arbor | Michigan | 48109 | — |
| Midwest Cutaneous Research Corporation | Clinton Township | Michigan | 48038 | — |
| Minnesota Clinical Study Center | Fridley | Minnesota | 55432 | — |
| Academic Dermatology Associates | Albuquerque | New Mexico | 87106 | — |
| Piedmont Medical Research Associates | Winston-Salem | North Carolina | 27103 | — |
| Wake Forest Univ School of Medicine | Winston-Salem | North Carolina | 27157 | — |
| Northwest Cutaneous Research Specialist | Portland | Oregon | 97210 | — |
| Oregon Medical Research Center, P.C. | Portland | Oregon | 97223 | — |
| Rivergate Dermatology | Goodlettsville | Tennessee | 37072 | — |
| Saint Mary's Centeral Wing Annex | Knoxville | Tennessee | 37917 | — |
| Tennessee Clinical Research Center | Nashville | Tennessee | 37221 | — |
| DermResearch Inc | Austin | Texas | 78759 | — |
| Texas Dermatology Research Institute | Dallas | Texas | 75230 | — |
| Center For Clinical Studies | Houston | Texas | 77030 | — |
| University Texas M.D. Anderson Cancer Center | Houston | Texas | 77030 | — |
| Center for Clinical Studies | Houston | Texas | 77058 | — |
| Virginia Clinical Research, Inc | Norfolk | Virginia | 23507 | — |
| Dermatology Associates P.L.L.C. | Seattle | Washington | 98101 | — |
| Rockwood Clinic, PS | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00090129, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 22, 2013 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00090129 live on ClinicalTrials.gov.